Dimensional Fund Advisors LP Boosts Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Dimensional Fund Advisors LP grew its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,785,009 shares of the life sciences company’s stock after buying an additional 12,766 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Integra LifeSciences were worth $52,014,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Capital Research Global Investors grew its holdings in shares of Integra LifeSciences by 37.7% during the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after purchasing an additional 1,621,655 shares during the last quarter. Norges Bank bought a new position in shares of Integra LifeSciences during the 4th quarter valued at $29,272,000. Boston Partners bought a new position in shares of Integra LifeSciences during the 1st quarter valued at $19,383,000. Cooke & Bieler LP grew its holdings in shares of Integra LifeSciences by 12.4% during the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after purchasing an additional 388,710 shares during the last quarter. Finally, Point72 Europe London LLP grew its holdings in shares of Integra LifeSciences by 54.9% during the 4th quarter. Point72 Europe London LLP now owns 719,663 shares of the life sciences company’s stock valued at $31,341,000 after purchasing an additional 255,201 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

IART has been the topic of a number of recent analyst reports. Citigroup cut their price target on shares of Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a report on Thursday, August 22nd. Truist Financial cut their price target on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday, July 30th. BTIG Research cut their price target on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a report on Wednesday, August 28th. JMP Securities cut their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a report on Tuesday, July 30th. Finally, Morgan Stanley raised their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.63.

Integra LifeSciences Trading Up 2.3 %

NASDAQ:IART opened at $17.87 on Friday. The company has a 50-day moving average price of $21.33 and a 200-day moving average price of $27.20. Integra LifeSciences Holdings Co. has a 12 month low of $16.96 and a 12 month high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 35.74, a P/E/G ratio of 0.60 and a beta of 1.10.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. During the same period last year, the company posted $0.71 EPS. Integra LifeSciences’s revenue was up 9.7% on a year-over-year basis. Equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.